Results 51 to 60 of about 83,236 (262)
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a membrane glycoprotein expressed by activated effector T cells (Teffs) and participates in the repression of T cell proliferation, cell cycle progression and cytokine production.
Yinghao Zhao +5 more
doaj +1 more source
A novel PLGA/PBAE polymer microparticle platform revolutionizes intermediate‐stage liver cancer treatment by co‐delivering panobinostat and IL‐12 via a single TACE‐like injection. This sustained‐release system overcomes tumor immunosuppression, triggers robust innate and adaptive immune responses, and establishes tertiary lymphoid structures ...
Hongzhe Yu +7 more
wiley +1 more source
CD28-Dependent CTLA-4 Expression Fine-Tunes the Activation of Human Th17 Cells
Summary: Previous work has demonstrated that Th17 memory cells but not Th1 cells are resistant to CD28/CTLA-4 blockade with CTLA-4 Ig, leading us to investigate the individual roles of the CD28 and CTLA-4 cosignaling pathways on Th1 versus Th17 cells. We
Scott M. Krummey +3 more
doaj +1 more source
Abstract Background Lipopolysaccharide‐responsive beige‐like anchor protein (LRBA) deficiency and cytotoxic T‐lymphocyte protein‐4 (CTLA‐4) insufficiency are recently described disorders that present with susceptibility to infections, autoimmunity, and lymphoproliferation.
Mehmet C. Catak +38 more
openaire +8 more sources
Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert +8 more
wiley +1 more source
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai +7 more
wiley +1 more source
L’immunotherapie par anticorps anti-CTLA-4, ipilimumab, est un traitement efficace du melanome metastatique utilise en monotherapie ou associe a la chimiotherapie (dacarbazine). L’effet therapeutique ne s’observe que chez 10 % a 20 % des patients, mais c’est la premiere fois qu’un medicament a un effet benefique sur la survie globale dans ce contexte ...
Caroline Robert, Christine Mateus
openaire +1 more source
A hierarchically selective immunotherapeutic nanoplatform, mGls@HEV‐MTP, selectively restores macrophage immunocompetence through GLS1‐mediated restoration of glutaminolysis‐fueled anaplerosis. Concurrently, it renders Staphylococcus aureus (S. aureus) more readily recognizable to the metabolically reprogrammed macrophages, thereby facilitating ...
Weinan Yang +17 more
wiley +1 more source
Background/Aims: Gastric cancer (GC) is one of the most common and lethal varieties of cancers. Anticancer activities of anti-CTLA-4 and anti-PD-1 antibodies have been explored in different cancers, including GC.
Bin Wang, Lei Qin, Mei Ren, Hao Sun
doaj +1 more source
CTLA-4 and the genetic predisposition to autoimmunity
Abstract Due to the wide spectrum of clinical manifestations and their epidemiological dimensions, autoimmune diseases represent an important medical issue. They are the consequence of the loss of immune tolerance to autoantigens, which in turn is a result of the interaction of environmental, as well as genetic factors.
T, Dallos, L, Kovacs
openaire +2 more sources

